Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 2/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.42 |
| ▸ | CBFB | Q13951 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30328922 | 0.76 | RET (0.52) | TYRO3DYRK1BKDM4EALDH1A1GAA | |
| SCHEMBL15915542 | 0.76 | RET (0.52) | TYRO3DYRK1BKDM4EALDH1A1GAA | |
| SCHEMBL23002873 | 0.74 | RPS6KA3 (0.41) | TYRO3DYRK1BKDM4EALDH1A1GAA | |
| SCHEMBL28523968 | 0.74 | CYP1A2 (0.46) | TYRO3DYRK1BKDM4EALDH1A1GAA | |
| SCHEMBL19286119 | 0.69 | RPS6KA3 (0.38) | TYRO3DYRK1BKDM4EALDH1A1GAA | |
| SCHEMBL28521892 | 0.69 | TYRO3 (0.34) | TYRO3DYRK1BKDM4EALDH1A1GAA | |
| SCHEMBL5786187 | 0.68 | SIRT2 (0.60) | TYRO3DYRK1BKDM4EPDE3BPDE3A | |
| SCHEMBL30572345 | 0.68 | GDA (0.44) | TYRO3DYRK1BKDM4EALDH1A1PRKD3 | |
| SCHEMBL340668 | 0.68 | GDA (0.44) | TYRO3DYRK1BKDM4EALDH1A1PRKD3 | |
| SCHEMBL3961933 | 0.68 | GDA (0.44) | TYRO3DYRK1BKDM4EALDH1A1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252605-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INST NAT SANTE RECH MED (FR) | 2018-06-13 | — | — | EP | disclosed |
| US-9125937-B2 | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-02-24 | — | — | US | disclosed |
| EP-2085390-A1 | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2009-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | CBR3, ADRB3, HRH4 | TYRO3 1006/4885DYRK1B 1361/4885KDM4E 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.